Physician profile
Arun Prasad
NPI 1619016052
$7,043.15
in general payments reported to CMS, 2019-2025
26 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $483 · 2021: $587 · 2022: $1,997 · 2023: $859 · 2024: $1,411 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,594.37 | 2022-2024 | Iolmaster 700 |
| Abbvie INC. | $866.89 | 2022-2025 | |
| Alcon Vision LLC | $801.40 | 2021-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Mallinckrodt Hospital Products INC. | $779.07 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $561.77 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Eyevance Pharmaceuticals LLC | $526.65 | 2019-2021 | |
| Allergan, INC. | $437.04 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $232.93 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $214.19 | 2023-2025 | Purified Cortrophin Gel |
| Thea Pharma INC. | $140.92 | 2022-2025 | Iyuzeh |
| Alkermes, INC. | $125.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $120.32 | 2019 | |
| Sun Pharmaceutical Industries INC. | $109.54 | 2019-2025 | |
| Amgen INC. | $102.10 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $72.54 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $56.16 | 2021 | |
| Oyster Point Pharma, INC. | $48.07 | 2024 | Tyrvaya, Ryzumvi, Tyrvaya |
| Horizon Therapeutics Plc | $46.07 | 2023 | Tepezza |
| Beaver-Visitec International, INC. | $43.11 | 2023-2024 | |
| Rayner Intraocular Lenses Limited | $41.10 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $31.87 | 2025 | Syfovre |
| Iridex Corporation | $26.62 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $22.85 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $16.78 | 2019 | |
| Oasis Medical, INC. | $12.98 | 2021 | |
| New World Medical,INC. | $12.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.